Lung ultrasound to direct chest physiotherapy in neonates

Neonates, Lung Disease

The primary purpose of this study is to evaluate the clinical effectiveness of LUS compared to current chest physiotherapy outcome measures in determining the need for and effect of physiotherapy on neonates. This will be done by comparing whether LUS is better at guiding CPT treatment than looking at the lungs with CXR and listening to the lungs using a stethoscope. Results may help us improve how CPT is delivered to babies in the future.

Category
Trial Status
Not yet recruiting
Trial Phase
Phase 0
ERM Project ID
103799
Trial contact details
Contact Person
Dr Judith Hough
What you need to know

Who can take part?

Neonates who:

  • Are admitted to the NICU.
  • Require mechanically ventilated.
  • Are identified as meeting criteria for physiotherapy assessment.
  • Have had a CXR in the previous 24 hours

Additionally, the parent/guardian must:

  • Have signed the consent form.
  • Be competent in understanding what the process will involve, assuring informed consent is obtained.

What is involved for you?

The purpose of this study is to evaluate the clinical effectiveness and feasibility of LUS compared to current CPT outcome measures of auscultation and CXR, in guiding decision-making around the use of CPT in neonates.

Participants will undergo a routine respiratory physiotherapy assessment on admission by a trained neonatal physiotherapist using CXR and auscultation and a CPT intervention plan determined. Participants will then undergo an LUS assessment by a physiotherapist blinded to the original assessment findings and diagnosis. LUS diagnosis and findings will be shared with the physiotherapist who provided the initial assessment and a re-evaluation of intended treatment will occur.

Trial dates

June 2024-July 2024

All research clinical trials news

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.

29

Feb

Highlighting Mater Research’s year of achievements: 2023 Annual Report

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.

27

Oct

Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.

23

May

Mater launches trial of Australian-first flu vaccine

Displaying results 1-3 (of 18)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|